Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eating Habits and Behavior in People Affected by Lipodystrophy: Observational Study (lipo-diet_2024)

11. November 2026 aktualisiert von: IRCCS Azienda Ospedaliero-Universitaria di Bologna

Title: Dietary Habits and Eating Behavior in People with Lipodystrophy: An Observational Study.

Purpose: The purpose of this study is to investigate and analyze the dietary habits and eating behaviors of patients diagnosed with lipodystrophy. Since there is currently a lack of specific data on how these patients approach nutrition, this research aims to provide essential information to improve nutritional guidelines. Additionally, the study seeks to understand if there is a relationship between eating behaviors and the patients' clinical data, such as blood test results and body measurements (anthropometric parameters).

Study Design:

This is an observational, cross-sectional, single-center study with a 2-year enrollment period. Participants will be recruited during their regular medical visits at the Endocrinology Unit of the IRCCS AOU di Bologna, Policlinico Sant'Orsola.

During the study, the following activities will take place:

Clinical Data Collection: Researchers will record body measurements and blood test results as part of standard clinical practice.

Questionnaires: Patients will be asked to complete four specific questionnaires (available in Italian and English) regarding their food frequency, eating behavior patterns, tendencies toward orthorexia, and physical activity levels.

Format: These questionnaires can be completed electronically via a RedCap link (taking approximately 20-30 minutes) or on paper.

Eligibility:

Inclusion Criteria: Adults (18 years or older) with a confirmed diagnosis of lipodystrophy who provide informed consent.

Exclusion Criteria: Patients with HIV-related lipodystrophy or those who cannot understand the languages in which the questionnaires are provided.

Duration and Participation:

The study will last a total of 2 years and 6 months. The first 2 years are dedicated to patient selection and recruitment, followed by 6 months for data analysis. The researchers aim to enroll 30 participants.

Studienübersicht

Status

Rekrutierung

Bedingungen

Detaillierte Beschreibung

1. Background and RationaleLipodystrophy refers to a rare and heterogeneous group of syndromes characterized by the total or partial loss of subcutaneous adipose tissue. This condition leads to severe metabolic complications, such as marked insulin resistance, early-onset diabetes, severe hypertriglyceridemia, and hepatic steatosis (fatty liver).A key factor in this pathology is hypoleptinemia (deficiency of the hormone leptin), which plays a crucial role in regulating energy balance. The lack of leptin disrupts satiety signals, often resulting in hyperphagia (insatiable hunger), with energy intake potentially exceeding requirements by up to 40%. While lifestyle and dietary modifications are considered the "cornerstone" of treatment, there is currently a significant lack of structured data and evidence-based nutritional guidelines for these patients.2. Study ObjectivesPrimary Objective: To identify, analyze, and describe the lifestyle of patients with a focus on dietary habits, eating behaviors, and physical activity.Secondary Objective: To explore the relationship between these behaviors and clinical data, including anthropometric measurements and biochemical (blood) parameters.3. Study Population and EligibilityThe study aims to enroll 30 patients managed at the Endocrinology Unit of the IRCCS AOU di Bologna, Policlinico Sant'Orsola.Inclusion Criteria: Male and female adults (≥ 18 years old) with a confirmed diagnosis of lipodystrophy who provide written informed consent.Exclusion Criteria: Patients with HIV-related lipodystrophy or those unable to understand the languages in which the questionnaires are provided.4. Study Design and MethodologyThis is a prospective, cross-sectional, observational, single-center study. Data will be collected during routine endocrinological visits through the following means:A. Clinical and Biochemical ParametersAnthropometric Data: Weight, height, BMI, waist and hip circumference, and body fat percentage.Biochemical Data: Fasting plasma glucose, HbA1c, full lipid profile (total cholesterol, HDL, LDL, triglycerides), liver enzymes (AST, ALT), kidney function, insulin levels, and HOMA-IR.B. Self-Assessment QuestionnairesParticipants will complete four validated tools (estimated time: 30 minutes, via RedCap or paper):Food Frequency Questionnaire (FFQ): To assess the intake frequency of 36 food items over the past 12 months.Three-Factor Eating Questionnaire (TFEQ-R18): To evaluate cognitive restraint, uncontrolled eating, and emotional eating.Teruel Orthorexia Scale (TOS): To measure orthorexic tendencies (obsession with healthy eating) in both "healthy" and "nervosa" dimensions.IPAQ-Short Form: To categorize physical activity levels as low, moderate, or high.5. Study Duration and AnalysisThe total study duration is 2 years and 6 months. This includes 2 years for patient recruitment and 6 months for data analysis. Statistical analysis will be performed using STATA 19 SE, comparing the observed dietary data with the 2024 LARN guidelines (Nutrient and Energy Reference Intake Levels) to identify deviations and correlations with metabolic health.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

30

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • Bologna
      • Bologna, Bologna, Italien, 40138
        • Rekrutierung
        • IRCSS Azienda Ospedaliero-Universitaria di Bologna

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

N/A

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Male and female patients over the age of 18 attending the outpatient service of the Endocrinology and Diabetes Prevention and Treatment Unit - U. Pagotto - IRCCS AOU in Bologna, Policlinico Sant'Orsola - Malpighi during their visit to the dedicated clinic.

Beschreibung

Inclusion Criteria:

  • Obtaining informed consent
  • Age 18 or older at the time of diagnosis
  • Diagnosis of lipodystrophy

Exclusion Criteria:

  • Failure to understand the language in which the questionnaires are administered
  • HIV-related lipodystrophy

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: PROSPECTIVE

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Food Frequency Questionnaire (FFQ)
Zeitfenster: baseline
baseline
Three-Factor Eating Questionnaire R-18 (TFEQ-R18)
Zeitfenster: baseline

Assessment of eating behavior using the 18-item validated questionnaire, evaluating three subscales: Cognitive Restraint (CR), Uncontrolled Eating (UE), and Emotional Eating (EE). Items are scored on a 4-point scale and converted to a 0-100 scale per domain, where higher scores indicate higher expression of the specific behavior.

baseline
Teruel Orthorexia Scale (TOS)
Zeitfenster: baseline
baseline
International Physical Activity Questionnaire - Short Form (IPAQ-Short Form)
Zeitfenster: baseline
baseline

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Body Mass Index (BMI)
Zeitfenster: baseline

Assessment of body weight status using BMI, calculated as weight in kilograms divided by height in meters squared (kg/m2).

baseline
Body Fat Percentage
Zeitfenster: baseline

Evaluation of total body fat composition measured via anthropometric assessment/bioelectrical impedance analysis (BIA).

baseline
Waist-to-Hip Ratio (WHR)
Zeitfenster: baseline

Assessment of abdominal obesity calculated as waist circumference divided by hip circumference.

baseline
Fasting Blood Glucose
Zeitfenster: baseline

Laboratory evaluation of serum/plasma fasting glucose concentration (mg/dL).

baseline
Glycated Hemoglobin (HbA1c)
Zeitfenster: baseline

Laboratory evaluation of glycated hemoglobin level (mmol/mol).

baseline
Fasting Serum Insulin
Zeitfenster: baseline

Laboratory evaluation of basal insulin levels micromol/mL.

baseline
Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Zeitfenster: baseline

index score

baseline
Lipid Profile Parameters
Zeitfenster: baseline
baseline

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

30. September 2025

Primärer Abschluss (Geschätzt)

30. September 2027

Studienabschluss (Geschätzt)

31. März 2028

Studienanmeldedaten

Zuerst eingereicht

4. März 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

11. November 2026

Zuerst gepostet (Tatsächlich)

16. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

16. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

11. November 2026

Zuletzt verifiziert

1. März 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • lipo-diet_2024

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .